Maravai LifeSciences (MRVI) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 116.5% versus a loss of 12.2%. Over five years, SUPN leads with a +33.1% price change compared with -80.6% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $2.45 billion), about 1.1 times the size, while Supernus Pharmaceuticals is growing revenue faster (+8.6% vs -28.3%).
Supernus Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.4% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | SUPN |
|---|---|---|
| Share price | $7.21 | $42.14 |
| Market cap | $2.67B | $2.45B |
| 1-day change | -2.96% | -2.11% |
| YTD return | +121.85% | -15.21% |
| 1-year return | +116.52% | -12.21% |
| 5-year return | -80.56% | +33.10% |
| Forward P/E | — | 9.45 |
| EPS (TTM) | $-0.53 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $718.95M |
| Revenue growth (YoY) | -28.34% | +8.63% |
| Net income (latest FY) | $-130.77M | $-38.55M |
| Gross margin | 18.30% | 89.63% |
| Operating margin | -115.89% | -8.66% |
| Net margin | -70.41% | -5.36% |
| 52-week high | $9.42 | $59.68 |
| 52-week low | $2.55 | $40.51 |
| Distance from 52-week high | -23.46% | -29.39% |
| Analyst consensus | buy | none |
| Avg. price target upside | +8.60% | +46.54% |
| Average volume | 3.36M | 756.95K |
| Shares outstanding | 148.99M | 58.22M |
| Employees | 415 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed SUPN by 128.7 percentage points over the past year.
- Supernus Pharmaceuticals is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- Supernus Pharmaceuticals grew revenue faster in its latest fiscal year (+8.63% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
MRVI vs SUPN FAQ
Which is bigger, Maravai LifeSciences or Supernus Pharmaceuticals?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $2.45B for Supernus Pharmaceuticals (SUPN).
Which stock has performed better over the past year, MRVI or SUPN?
MRVI returned +116.52% over the past 12 months, compared with -12.21% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.